Dina Lozofsky serves as the Senior Director of Business Development, Physical Sciences and Engineering. Dina joined UCLA TDG in August 2019, bringing more than 25 years’ experience working in and around science and technology in Southern California. Most recently, Dina was the Executive Director at Biocom, leading Biocom’s efforts to help grow and support the LA life science industry, raising awareness around the regional cluster’s many research accomplishments. Before joining Biocom, Dina was the Associate Director for Licensing and Business Development at UC Santa Barbara’s Office of Technology and Industry Alliances, where she managed a program to mentor and support startup companies formed around UCSB technology.
Dina has deep experience in intellectual property (IP) management and in leveraging IP to structure strategic alliances for both companies and universities, facilitating university collaboration with industry and fostering startup formation and licensing. She was also Vice President, Corporate Development for Solarmer Energy, a next generation solar startup spun out of UCLA, leading the company’s efforts in strategic relationships, business development, intellectual property, legal affairs, and marketing and worked with BTG International as Associate Vice President in their acquisitions group.
Dina holds a BS in Aerospace Engineering from MIT, an MBA from USC’s Marshall School of Business and is a registered Patent Agent.
Bardia Moayedi is a corporate and securities partner, chair of the firm’s Technology Industry Group and co-chair of the firm's Life Sciences Industry Group. He primarily advises emerging growth and public companies throughout their life cycles as well as venture capital and private equity firms, particularly in the life sciences, high-technology, financial technology, food and beverage, and clean-technology industries.
Bardia has significant experience representing companies and financial firms in a broad range of general corporate governance and transactional matters, including venture capital financings, mergers and acquisitions, debt offerings, spin-offs/divestitures, joint ventures, IPOs, follow-on offerings, and tender offers. He is a trusted advisor, often serving as the go-to outside counsel or lead counsel to his clients.
Prior to attending law school, Bardia worked at a prominent investment bank, where he focused on hedge funds and private equity funds. As an undergraduate, he played ice and roller hockey at UCLA.
Maysam Pessian is an associate in the Century City office of Wilson Sonsini Goodrich & Rosati. His practice focuses on patent prosecution and intellectual property counseling, serving clients in a wide range of technology fields, including the pharmaceuticals and biotechnology industries.
Brian M. Paegel (rhymes with “bagel”) earned his undergraduate degree in chemistry from Duke University and his doctoral degree in chemistry from UC Berkeley working on miniaturized and integrated DNA sequencing technology development in collaboration with the Human Genome Project. He pursued postdoctoral studies in chemical biology and molecular evolution at Scripps Research. There, he studied the continuous evolution of catalytic RNAs, developing microfluidics for automation, reaction monitoring, and droplet compartmentalization. He was the recipient of both a NIH National Research Service Award (F32) and a Pathway to Independence Award (K99/R00). In 2008, Paegel was appointed to the Scripps chemistry faculty, starting his independent career at the new east coast campus of Scripps Research in Jupiter, Florida. He received the NIH Director’s New Innovator award and an NSF CAREER award in recognition of his contributions in reaction miniaturization for enzyme evolution, and Scripps granted him tenure in 2017 for his work in the field of DNA-encoded libraries and drug discovery technology development. In 2019, Paegel rejoined the University of California System where he is Professor in the Departments of Pharmaceutical Sciences, Chemistry, and Biomedical Engineering at Irvine. His laboratory aims to deliver advanced parallel synthesis and screening platforms to support cross-disciplinary translational research initiatives. Paegel is deploying these platforms to eliminate the canonical sense of what is “druggable” within the cellular milieu and to democratize the discovery of new medicines. To this end, he has co-founded four start-up companies in the biotechnology and drug discovery space.
Our tagline, HR that Makes a Difference™, defines what we do. It emphasizes that human resources is a key driver of growth and contributes to a business’s bottom line. This is what sets Insperity apart.
Insperity has a long history of improving the success equation of small and midsize businesses across the country – because when businesses succeed, communities prosper.
And in today’s changing business environment, it’s our privilege to take care of an organization’s most valuable asset: its people.
HATCHspaces ®, LLC is a Los Angeles-based real estate development platform focused on simplifying the process of scientific innovation by creating purpose-built life sciences facilities for companies emerging from academic and incubator networks. With properties in various regional submarkets, HATCHspaces’® mission is to deliver the life science community state-of-the-art lab facilities at varying scales, allowing regions to retain early-stage bioscience and biotechnology start-ups emerging from research environments.
NexCore Group is a national healthcare real estate investment and development company that focuses on acquiring, developing, owning and managing healthcare facilities including medical office buildings, wellness facilities, ambulatory surgery centers, single and multi-specialty physician buildings, life sciences facilities, seniors housing communities and transitional rehabilitation centers. NexCore has completed $4.7 billion in healthcare real estate transactions throughout 29 states, developed and acquired over 14.3 million square feet of healthcare properties across the country and currently manages over $2.9 billion of healthcare facilities spanning 7.3 million square feet. The company has been recognized repeatedly as one of the Top Healthcare Real Estate Developers in the U.S. by Modern Healthcare and HREI.
Founded in 1938, Snell & Wilmer is a full-service business law firm with more than 450 lawyers practicing in 16 locations throughout the United States and in Mexico, including three offices in California. The firm represents clients ranging from large, publicly traded corporations to small businesses, individuals and entrepreneurs. Snell & Wilmer’s life science and medical technology lawyers currently represent a diverse client base from the bioscience, pharmaceutical (both prescription and OTC), medical device and healthcare industries, ranging from large publicly traded organizations to early and mid-stage start-up companies. Clients include manufacturers, distributors, inventors, researchers, venture capitalists, angel investors, engineers, product designers and vendors, in their intellectual property, transactional, litigation and various other legal matters.
For over 28 years, Biocom California has helped move the life science industry forward with transformative resources that enable companies to make meaningful connections. Biocom California harnesses the collective power and experience of the most innovative and productive life science clusters in the world, with powerful advocacy and transformative programs to help companies in their quest to improve the human condition.
Wednesday, June 28, 2023
05:00 PM - 08:00 PM
The Water Grill
3300 Bristol St, Costa Mesa, CA 92626Register Now